Pridopidine in the pharmacological treatment of Huntington’s disease
Martin Michl, Katharina Schnopfhagen, Raphael M. Bonelli · Clinical Investigation · 2013
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Clinical Investigation · OMICS Publishing Group · article · 2013
Abstract
The available treatment options for Huntington’s disease (HD) are only symptomatic, partly with a limited symptom control and often accompanied by serious side effects. This review summarizes the current management of HD and elucidates why pridopidine might represent a turning point in the treatment of the condition. Pharmacology, clinical evidence, safety and tolerability of the drug will also be addressed. As pridopidine is a member of a new class of compounds, it opens up the field for new treatment strategies that might be more efficient in controlling motor symptoms, with fewer side effects than the treatment options currently available.
In a Phase II and III study, pridopidine significantly improved motor functions in Huntington patients with an adverse-event profile comparable to that of a placebo.
Open the resolved locator · 10.4155/cli.13.54
Metadata licence: OpenAlex metadata (CC0)